Oral showed no clear difference in renal parenchymal damage at 6 to 12 months: all included children… compared with IV followed by oral (11 days) therapy (moderate certainty).
Oral showed no clear difference in renal parenchymal damage at 6 to 12 months: children with renal… compared with IV followed by oral (11 days) therapy (moderate certainty).
Short duration (3 to 4 days) showed no clear difference in persistent bacteriuria after treatment compared with long duration (7 to 14 days) IV therapy (low certainty).
Short duration (3 to 4 days) showed no clear difference in recurrent UTI within 6 months compared with long duration (7 to 14 days) IV therapy (moderate certainty).
Short duration (3 to 4 days) showed no clear difference in persistent renal damage at 3 to 6 months: all included children with… compared with long duration (7 to 14 days) IV therapy (moderate certainty).
Short duration (3 to 4 days) showed no clear difference in persistent renal damage at 3 to 6 months: children with initial… compared with long duration (7 to 14 days) IV therapy (moderate certainty).
Different dosing regimens of aminoglycosides (daily showed no clear difference in persistent bacteriuria after 1 to 3 days of treatment compared with 8 hourly) (low certainty).
Different dosing regimens of aminoglycosides (daily showed no clear difference in hearing impairment following treatment compared with 8 hourly) (low certainty).
It is very uncertain whether the intervention changes re‐infection (very low certainty).
It is very uncertain whether 10‐day trimethoprim changes persistent bacteriuria compared with 10‐day trimethoprim+sulfamethoxazole (very low certainty).
It is very uncertain whether 10‐day trimethoprim changes persistent symptoms compared with 10‐day trimethoprim+sulfamethoxazole (very low certainty).
It is very uncertain whether 10‐day trimethoprim changes recurrence compared with 10‐day trimethoprim+sulfamethoxazole (very low certainty).
It is very uncertain whether 10‐day cefadroxil changes persistent bacteriuria compared with 10‐day ampicillin (very low certainty).
It is very uncertain whether 10‐day cefadroxil changes persistent symptoms compared with 10‐day ampicillin (very low certainty).
It is very uncertain whether single‐dose fosfomycin changes persistent bacteriuria compared with single‐dose netilmicin (very low certainty).
It is very uncertain whether single‐dose fosfomycin changes recurrence compared with single‐dose netilmicin (very low certainty).
It is very uncertain whether single‐dose changes persistent bacteriuria compared with conventional 10‐day antibiotic treatment (very low certainty).
It is very uncertain whether single‐dose changes persistent symptoms compared with conventional 10‐day antibiotic treatment (very low certainty).
It is very uncertain whether single‐dose changes persistent bacteriuria and symptoms compared with conventional 10‐day antibiotic treatment (very low certainty).
It is very uncertain whether single‐dose changes recurrence compared with conventional 10‐day antibiotic treatment (very low certainty).